A Phase 3b, Open-label Study Evaluating the Long-term Safety and Efficacy of Elexa-caftor/Tezacaftor/Ivacaftor Combination in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (VX20-445-119)
The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in par-ticipants with CF who are 6 years of age and older with F/MF geno-types.
Study details
Study-ID: NCT04545515, 2020-001404-42
Study-ID: NCT04545515, 2020-001404-42
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
